Working with the murine epidermal-derived dendritic cell (DC) line XS52, we have observed previously that antigenspecific interaction with T cells stimulates their "terminal maturation" into fully professional DC. In this study we examined the impact of dexamethasone (DEX) on this T cell- 
Introduction
Glucocorticoids (GCs) 1 have been used effectively for several decades as potent immunosuppressive agents in treating inflammatory diseases, including those that are mediated by T cells. With respect to pharmacological mechanisms of action, GCs are known to inhibit several immunologically relevant activities of monocytes and macrophages, including ( a ) secretion of cytokines and prostaglandins; ( b ) expression of surface receptors for complement and immunoglobulins; ( c ) phagocytosis and pinocytosis; and ( d ) bactericidal and fungicidal activities. It is also known that GCs inhibit certain functions of T cells, including the secretion of IL-2, and their mitogenic potential. Based on these observations, the immunosuppressive activities of GCs have been attributed primarily to their influence on monocytes/macrophages and on T cells (1) (2) (3) (4) . On the other hand, extensive studies by Steinman and others have now established the concept that dendritic cells (DC), rather than macrophages and monocytes, are responsible for the initiation of T cell-mediated immunity (for review see reference 5). A critical question, then, concerns the impact that GCs have on DC, a question that has yet not been addressed, primarily due to the unavailability of stable DC lines for in vitro experimentation.
We have established recently long-term DC lines from the epidermis of newborn BALB/c mice (6) . These lines, termed "XS series," retain important features of resident epidermal DC (Langerhans cells), including their surface phenotype (6) , antigen (Ag)-presenting capacity (6, 7) , and cytokine and cytokine receptor mRNA profiles (8) (9) (10) . Working with these XS DC lines, we have observed that Ag-specific DC-T cell interaction delivers cell activation signals, not only forward to the responding T cells, but also back to the DC. More specifically, upon Ag-specific interaction with T cells, the XS52 cells ( a ) secrete relatively large amounts of IL-1 ␤ (11), IL-6, and TNF ␣ (Kitajima, T., and A. Takashima, unpublished observations); ( b ) elevate their expression of CD86 (B7-2) (12); and ( c ) lose surface expression of CD115 (colony-stimulating factor-1 receptor [CSF-1R]) and proliferative responsiveness to CSF-1 (13) . Incubation with T cells or Ag alone fails to induce any of these changes, indicating that each requires both T cells and Ag. These observations indicate that during Ag presentation bidirectional signaling events trigger a series of changes known as "T cell activation" and a second series of changes in the DC. Because IL-1 ␤ , IL-6, TNF ␣ , and CD86 are all required for full activation of T cells, the induced changes in DC appear to represent their critical transition into fully professional Ag-presenting cells, a process that has been termed "T cell-mediated terminal maturation" (11, 13) . Pharmacologic interference with this transition may serve as a method of suppressing T cell-mediated immune responses.
Methods
Cells. The XS52 line is a long-term DC line established from the epidermis of a newborn BALB/c mouse (6) . This line has been expanded in growth medium consisting of complete RPMI supplemented with rGM-CSF (1-2 ng/ml) and culture supernatant (10% vol/vol) collected from the NS01 or NS47 stromal cell line (6, 14) . Features of the XS52 line have been described elsewhere (6) (7) (8) (9) (10) . As responding T cells, we used the KLH-specific Th1 clone HDK-1 (15) . The capacity of XS52 cells to activate this T cell clone has been described previously (6, 7) .
Activation of DC and/or T cells. XS52 cells and HDK-1 T cells were cocultured in the presence of KLH (100 g/ml) and then examined for cytokine secretion, phenotypic changes, and proliferative responses to CSF-1, as described before (11, 13) . In some experiments, the XS52 DC and HDK-1 T cells were activated independently with LPS (20 ng/ml) and Con A (4 g/ml), respectively (11) . Dexamethasone (DEX) purchased from Sigma Immunochemicals (St. Louis, MO) was dissolved at 10 Ϫ 2 M in ethanol and added to the above cultures at concentrations of 10 Ϫ 9 -10 Ϫ 6 M. Cytokine assays. Culture supernatants were examined for IL-1 ␤ , IL-2, IL-6, IFN ␥ , and TNF ␣ with ELISA kits (Genzyme, Cambridge, MA), as described previously (11) . Cytokine concentrations are shown in nanograms per milliliter as calculated from standard curves made with recombinant cytokines.
Flow cytometry. XS52 cells and HDK-1 T cells were readily distinguishable in FACS ® by forward versus side light scatter, thus allowing us to characterize the surface phenotype of each cell type from a mixed population (13) . Samples were stained with the anti-CD115 mAb 2E-11 (16) , a generous gift from Dr. G. Gilmore (Western Pennsylvania Cancer Institute, Pittsburgh, PA) or with mAb against CD25, CD44, or CD86 (Pharmingen, San Diego, CA).
Proliferation assays. T cell-mediated changes in the proliferative responsiveness of XS52 cells to CSF-1 were examined as described previously (13) . Briefly, XS52 cells (1 ϫ 10 4 cells/well) were preincubated in 96-well plates for 24 h with ␥ -irradiated (3,500 rad) HDK-1 T cells (3 ϫ 10 3 cells/well) in the presence of KLH. Subsequently, these cells were fed with 10 ng/ml of rCSF-1 (Gibco Laboratories, Grand Island, NY) and then tested for [ 
Results
Impact of DEX on cytokine secretion by DC. We detected relatively large amounts of IL-1 ␤ , IL-6, and IFN ␥ and modest amounts of IL-2 in supernatants collected from "complete" cocultures containing XS52 DC, HDK-1 T cells, and Ag (KLH) (Fig. 1, top ) . By contrast, none of these cytokines was detectable in significant amounts in supernatants collected from "incomplete" cocultures that lacked one or more of these components, indicating that all the three (DC, T cells, and Ag) are required for cytokine secretion. With respect to their source, we have observed previously that ( a ) IL-1 ␤ and IL-6 are secreted primarily by XS52 DC; ( b ) TNF ␣ is secreted by both XS52 cells and HDK-1 T cells; and ( c ) IFN ␥ and IL-2 are secreted exclusively by T cells (11) (Kitajima, T., and A. Takashima, manuscript in preparation). Importantly, when DEX was added continuously to the complete cocultures, the secretion of IL-1 ␤ and IL-6 was inhibited in a dose-dependent manner, with significant inhibition at 10 -10 Ϫ 6 M. DEX also inhibited, albeit partially, the secretion of TNF ␣ . Because of the relatively small amounts of IL-2, even in the absence of DEX, we were not able to study in a quantitative fashion the impact of DEX on its secretion. Nevertheless, in each of three independent experiments, IL-2 became undetectable when DEX was added at 10 Diminished secretion of DC-derived cytokines does not necessarily mean that DEX acts directly on the DC, because IL-1 ␤ secretion, for example, is triggered by coupling of surface class II and CD80/CD86 molecules (on XS52 cells) with their respective ligands (on HDK-1 cells) (11) . DEX may have acted primarily on the T cells, inhibiting their expression of these ligands (i.e., the T cell receptor-CD3 complex and CD28/CTLA-4) and diminishing the secretion of IL-1 ␤ by DC. To determine whether DEX had acted directly on DC, we next stimulated XS52 cells with LPS in the absence of T cells. As noted in Fig. 1 ( bottom ) , LPS-induced secretion of IL-1 ␤ and IL-6 by the XS52 cells was inhibited by DEX in a dose-dependent fashion, once again, with significant inhibition at 10 -10 Ϫ 6 M. Moreover, LPS-driven secretion of TNF ␣ by XS52 cells was inhibited almost completely. Thus, DEX can act directly on DC to inhibit the secretion of IL-1 ␤ , IL-6, and TNF ␣ . When the HDK-1 T cells were stimulated with Con A (in the absence of DC), they secreted significant amounts of IL-2, IFN ␥ , and TNF ␣ . Although DEX inhibited IL-2 secretion effectively, only marginal, if any, inhibition was observed for the secretion of IFN ␥ and TNF ␣ . Thus, the effect of DEX on cytokine secretion by T cells is relatively specific for IL-2.
Impact of DEX on CD115 expression and proliferative responsiveness to CSF-1. XS52 DC proliferate vigorously, not only in response to GM-CSF, but also to CSF-1 (9) . Upon Agspecific interaction with HDK-1 T cells, however, they lose both their surface expression of CD115 (CSF-1R) and their proliferative responsiveness to CSF-1 (13) . When DEX was added to complete cocultures of XS52/HDK-1/KLH, the XS52 cells retained their expression of CD115 (Fig. 2 A ) . In doseresponse experiments, 80% protection was achieved at 10 Ϫ 6 M. Treatment of the XS52 cells with IFN ␥ alone was sufficient to abrogate CD115 expression, corroborating our previous report (13) . Importantly, the IFN ␥ -induced downregulation of CD115 (in the absence of T cells) was also prevented by DEX, with complete protection obtained at 10 Ϫ 7 M. Thus, DC are a direct target of DEX for this effect as well.
A critical question then concerned whether DEX would allow XS52 cells to retain their proliferative responsiveness to CSF-1 after interaction with T cells. To address this question, we first identified DEX concentrations that would not inhibit XS52 cell growth directly; DEX up to 10 Ϫ 8 M had only a modest effect, whereas above 10 Ϫ 7 M it became inhibitory (Fig. 2  B ) . Subsequently, DEX was added to the complete XS52/ HDK-1/KLH cocultures at concentrations below 10 Ϫ 7 M. In the absence of DEX, the XS52 cells lost their proliferative responsiveness to CSF-1 (Fig. 2 C ) . Importantly, DEX at 10 Ϫ 8 M protected substantially (by ‫ف‬ 50%) their proliferative responsiveness to CSF-1. In each of the three independent experiments, DEX (10 Ϫ 8 or 10 Ϫ9 M) produced significant, albeit incomplete, protection of this activity. This most likely reflects the fact that DEX as high as 10 Ϫ6 M was required to preserve the full expression of CD115. Nevertheless, it is evident that DEX protects, at least partially, against T cell-dependent loss of proliferative responsiveness to CSF-1.
Impact of DEX on CD86 expression. As has been reported for epidermal DC (i.e., Langerhans cells) (17) (18) (19) (20) , from which the XS lines were established originally, XS52 cells constitutively express only negligible, if any, CD80 (B7-1) and CD86 (B7-2) (6). However, they do increase the expression of CD86 upon Ag-specific interaction with HDK-1 T cells (Fig. 3 A) . Because ligation of CD28 (on T cells) with CD80/CD86 (on DC) is required for maximal activation of T cells (for review see reference 21), this regulation represents a critical event in the maturation of DC into fully potent Ag-presenting cells. On the other hand, the responding HDK-1 T cells increase their expression of CD25, one component of the IL-2R complex, upon Ag-specific interaction with XS52 DC (Fig. 3 B) . Therefore, both DC and T cells undergo critical phenotypic changes during Ag presentation. Importantly, DEX prevented, in a dose-dependent manner, CD86 induction in the XS52 cells, with a significant reduction at 10 Ϫ9 M and complete inhibition at 10 Ϫ8 M. By contrast, DEX, even at higher concentrations (up to 10 Ϫ6 M), inhibited CD25 induction in T cells only marginally.
To dissect further the differential influence of DEX on DC and T cells, we activated DC and T cells separately with LPS and Con A, respectively (Fig. 4) . In response to LPS stimulation, the XS52 cells elevated CD86 and diminished CD115 expression, whereas the HDK-1 cells elevated their expression of CD25, CD28, and CD44. Importantly, DEX at 10 Ϫ7 M inhibited completely both CD86 upregulation and CD115 downregulation in the XS52 cells. By contrast, DEX at the same concentration had negligible, if any, effects on the expression of CD25, CD28, and CD44 by T cells. These results support our hypothesis that DC are a relevant target of DEX during Ag presentation.
Discussion
Our data demonstrate a novel mechanism through which GCs suppress T cell-mediated immunity, by preventing T cellmediated terminal maturation of DC. To recapture the es- (Bottom) HDK-1 T cells were cultured for 24 h in the presence or absence of Con A (4 g/ml) and/or DEX (10 Ϫ7 M) and then examined for the expression of CD25, CD28, and CD44. Data shown are the mean specific fluorescence intensity (mean intensity with a specific mAb minus mean intensity with an isotype-matched control IgG). All the data represent at least three independent experiments. sence of our observations, the XS52 DC line undergoes, in response to Ag-specific interaction with T cells, a series of changes that includes (a) secretion of IL-1␤, IL-6, and TNF␣; (b) loss of surface expression of CD115 (CSF-1R) and proliferative responsiveness to CSF-1; and (c) heightened expression of CD86. Each of these changes was inhibited effectively and uniformly by DEX. By contrast, the influence of DEX on T cells was selective, inhibiting only IL-2 secretion, without affecting significantly other changes that accompany Ag presentation. Based on these observations, we conclude that DC are a relevant target of DEX.
The observation that DEX inhibits cytokine secretion by DC is not unexpected, given that GCs are known to downregulate the capacity of monocytes and macrophages to secrete IL-1 (22) (23) (24) (25) , , and TNF␣ (27) (28) (29) . However, our observation differs in several respects from these earlier reports. First, we have studied DC, which play an even more important role than monocytes and macrophages during the induction of primary T cell responses (5) . Second, our experimental system uses Ag-specific interaction with T cells as a stimulus to trigger cytokine secretion, reflecting in vivo Ag presentation more closely than do other systems that use artificial stimuli, such as LPS or phorbol esters. In fact, the identity and biological relevance of each stimulus are especially important, because DEX has been reported to inhibit IL-1␤ secretion by LPS-stimulated monocytes but to augment IL-1␤ secretion triggered by phorbol myristate acetate (30) . Finally, we have demonstrated that DEX differentially affects cytokine secretion by DC compared with T cells. The secretion of IL-1␤, IL-6, and TNF␣ by DC was inhibited uniformly by DEX, whereas its inhibitory effect on cytokine secretion by T cells was selective for IL-2. Even more strikingly, DEX inhibited DC, but not T cells, from secreting TNF␣. Taken together, these experiments document a new biological activity of DEX, i.e., the inhibition of T cellstimulated cytokine secretion by DC.
Our results provide new information with respect to mechanisms of GC action in suppressing T cell-mediated inflammatory diseases. Because IL-1␤, IL-6, and TNF␣ are all prototypic proinflammatory cytokines, interference with their secretion by DC is the most obvious mechanism. A second mechanism is derived from the diminished CD115 expression. Not only does the absence of CD115 abrogate the proliferative responsiveness of DC to CSF-1, it also may affect maturation. This is because GM-CSF and CSF-1 both promote the growth of XS52 cells, whereas only GM-CSF promotes maturation into potent Ag-presenting cells (8) , and the loss of CD115 would make them selectively responsive to GM-CSF, thereby facilitating maturation. Thus, DEX-mediated protection of CSF-1 responsiveness serves as a second mechanism of immunosuppression by GCs. Finally, it is well established that CD80/CD86 (and perhaps other B7-related molecules) delivers critical costimulatory signals to T cells (21) . In fact, anti-CD86 mAb and CTLA4-Ig fusion proteins each block XS52 cell-dependent activation of HDK-1 T cells (Xu, S., and A. Takashima, unpublished observations). Because XS52 cells, like resident epidermal DC, express only negligible, if any, CD80 and CD86, they must be acquired during Ag presentation to deliver T cell activation signals. Thus, interference with the acquisition of CD86 is a third mechanism by which GCs may suppress T cell activation. Although the in vivo relevance of each of these pathways remains to be determined, this study provides a basis for the new concept that GCs suppress T cellmediated immune responses by interfering with the terminal maturation of DC.
The proposed concept is mirrored in other reports. For instance, DEX has been shown to inhibit Ag-presenting celldependent activation of T cells, but not Ag-presenting cellindependent activation, as is triggered by phorbol esters and calcium ionophores (31) . DEX is also known to downregulate the costimulatory capacity of Langerhans cells (32) . More recently, DEX has been shown to downregulate the expression of CD80 and CD86 and to diminish the T cell stimulatory capacity by DC (33) . It is also important to emphasize that this proposal does not conflict with the concept that DEX affects the function of T cells. As predicted by reports from many investigators (31, 34, 35) , DEX did inhibit IL-2 secretion by T cells in our experimental system. Although somewhat conflicting results have been reported with respect to the impact of GCs on the expression (and function) of the IL-2R complex (35-40), we observed that DEX had only a negligible effect on DC-stimulated expression of CD25 (␣ chain). Importantly, DEX failed to inhibit the expression of CD28 or CD44 or to affect the secretion of IFN␥ or TNF␣. Thus, DEX does not inhibit all of the changes associated with T cell activation. It will be interesting to determine whether impaired maturation of DC (e.g., failure to secrete cytokines and express CD86) plays a causative role in DEX-sensitive changes (e.g., IL-2 secretion), but not DEX-resistant changes in T cells (e.g., secretion of IFN␥). Our experimental system will serve as a useful method to test this and other relevant questions regarding impact of GCs and other immunosuppressive drugs on Ag-specific DC-T cell interaction. Moreover, it may be possible to use this system to search for and to develop new compounds that inhibit DC maturation selectively.
